University Hospital, Toulouse: Multiple Myeloma trials

The registry lists 14 Multiple Myeloma studies with University Hospital, Toulouse as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.RecruitingNCT06846905
• ICOPE Program Feasibility in the Management of Myeloma PatientsRecruitingNCT06247189Not applicable
• Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell ExaminationRecruitingNCT05945524Not applicable
• Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"RecruitingNCT04888039
• Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological MalignancyCompletedNCT05101759Not applicable
• "FU-IFM2009" Database Post IFM/DFCI 2009 StudyStatus unknownNCT03679351
• Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
• Myeloma Treatment in Real LifeCompletedNCT03638232
• Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
• Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone InductionCompletedNCT02405364Phase 2
• Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaCompletedNCT02197221Phase 3
• Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
• Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
• IFM 99-02 Thalidomide in MyelomaCompletedNCT00222053Phase 3